113 related articles for article (PubMed ID: 2672605)
1. [What are tumor markers, and what is their value?].
von Kleist S
Wien Klin Wochenschr; 1989 Jul; 101(14):459-63. PubMed ID: 2672605
[TBL] [Abstract][Full Text] [Related]
2. [Tumor markers--how they should be applied].
Stieber P; Heinemann V; Schalhorn A
MMW Fortschr Med; 2005 May; 147(20):35, 37-9. PubMed ID: 15957858
[TBL] [Abstract][Full Text] [Related]
3. [Tumor marker analyses--valuable tools if used correctly].
Børmer OP; Paus E; Nustad K; Theodorsen L
Tidsskr Nor Laegeforen; 1994 Nov; 114(28):3317-20. PubMed ID: 7809890
[TBL] [Abstract][Full Text] [Related]
4. [Immunologic tumor diagnosis].
Schmolke B
Z Lymphol; 1990 Dec; 14(2):58-61. PubMed ID: 2087871
[TBL] [Abstract][Full Text] [Related]
5. Dynamic use of tumor markers, rationale-clinical applications and pitfalls.
Gion M; Mione R; Barioli P; Dittadi R
Anticancer Res; 1996; 16(4B):2279-84. PubMed ID: 8694556
[TBL] [Abstract][Full Text] [Related]
6. [Clinical relevance of tumor markers].
Lamerz R
Wien Klin Wochenschr; 1989 Jul; 101(14):464-72. PubMed ID: 2672606
[TBL] [Abstract][Full Text] [Related]
7. [Basic concepts in the use of tumor markers in the diagnosis and follow-up of malignant bladder neoplasms].
Moreno Sierra J; Gómez Ruiz JJ; Ortega Heredia MD; Blanco Jiménez E; Silmi Moyano A; Blázquez Izquierdo J; Corral Rosillo J; Rodríguez Molina J; Ramírez Fernández JC; Resel Estévez L
Arch Esp Urol; 1993 Apr; 46(3):187-98. PubMed ID: 8512354
[TBL] [Abstract][Full Text] [Related]
8. [Tumor markers in gynecology].
Fuith LC; Artner-Dworzak E; Daxenbichler G
Wien Klin Wochenschr; 1989 Jul; 101(14):489-91. PubMed ID: 2672608
[TBL] [Abstract][Full Text] [Related]
9. [Tumor markers in the upper intestinal tract--stomach and pancreas].
Pointner R; Conrad F; Schwab G
Wien Klin Wochenschr; 1989 Jul; 101(14):482-4. PubMed ID: 2773485
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
[TBL] [Abstract][Full Text] [Related]
11. The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours.
Venkitaraman R; Johnson B; Huddart RA; Parker CC; Horwich A; Dearnaley DP
BJU Int; 2007 Jul; 100(1):30-2. PubMed ID: 17552950
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
[TBL] [Abstract][Full Text] [Related]
13. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
14. Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results.
Zervoudis S; Peitsidis P; Iatrakis G; Panourgias E; Koureas A; Navrozoglou I; Dubois JB
J BUON; 2007; 12(4):487-92. PubMed ID: 18067207
[TBL] [Abstract][Full Text] [Related]
15. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.
Lokeshwar VB; Habuchi T; Grossman HB; Murphy WM; Hautmann SH; Hemstreet GP; Bono AV; Getzenberg RH; Goebell P; Schmitz-Dräger BJ; Schalken JA; Fradet Y; Marberger M; Messing E; Droller MJ
Urology; 2005 Dec; 66(6 Suppl 1):35-63. PubMed ID: 16399415
[TBL] [Abstract][Full Text] [Related]
16. Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness.
Forni F; Ferrandina G; Deodato F; Macchia G; Morganti AG; Smaniotto D; Luzi S; D'Agostino G; Valentini V; Cellini N; Giardina B; Scambia G
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1145-9. PubMed ID: 17689030
[TBL] [Abstract][Full Text] [Related]
17. [The value of CA 125 determination in the serum of patients with ovarian cancer].
Bartel U; Johannsen B; Elling D
Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
[TBL] [Abstract][Full Text] [Related]
18. Implications of prognostic markers in brain tumors.
Grzybicki DM; Moore SA
Clin Lab Med; 1999 Dec; 19(4):833-47. PubMed ID: 10572718
[TBL] [Abstract][Full Text] [Related]
19. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
20. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
